Business Context and Reporting Period
Company: LecTec Corporation (Note: Input metadata referenced "Axogen, Inc.", but the filing text identifies the registrant as LecTec Corporation).
Reporting Period: Fiscal year ended June 30, 2000.
Business Overview: LecTec designs, manufactures, and markets diagnostic electrocardiograph (ECG) electrodes, conductive hydrogels, and therapeutic patches for over-the-counter (OTC) drugs. The company operates in three primary product lines: conductive products, medical tapes, and therapeutic consumer products. It holds ISO 9001 and EN46001 quality certifications.
Key Financial Metrics
| Metric | Fiscal 2000 | Fiscal 1999 | Fiscal 1998 |
|---|---|---|---|
| Net Sales | $14,596,346 | $12,279,075 | $12,922,365 |
| Gross Profit | $5,121,217 | $4,093,561 | $3,715,032 |
| Gross Margin | 35.1% | 33.3% | 28.8% |
| Net Loss | $(2,859,276) | $(1,683,257) | $(404,061) |
| Loss Per Share (Basic/Diluted) | $(0.74) | $(0.43) | $(0.10) |
| Cash & Equivalents | $100,171 | $1,022,025 | $2,186,532 |
| Working Capital | $1,512,561 | $3,497,926 | $5,335,861 |
| Debt (Current Note Payable) | $837,542 | $0 | $0 |
| Long-Term Obligations | $31,184 | $20,868 | $222,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 18.9% to $14.6 million, driven primarily by a 189.2% surge in therapeutic consumer product sales (TheraPatch brand and new acne product sales to Johnson & Johnson). This growth was partially offset by a 4.0% decline in conductive products and a 29.0% decline in medical tapes.
- Strategic Exit: The company adopted a plan to exit the low-margin medical tape business effective June 30, 2000. This resulted in a $730,000 charge ($645,000 asset impairment and $85,000 inventory write-down).
- Profitability: Despite a 25.1% increase in gross profit (due to a favorable shift in sales mix toward higher-margin therapeutic products), the company reported a net loss of $2.86 million. This loss was driven by increased sales and marketing expenses (up 67.9% to $3.67 million) and the medical tape exit charge.
- Liquidity: Cash and cash equivalents decreased by $921,854 to $100,171. Working capital declined significantly from $3.5 million to $1.5 million, and the current ratio dropped from 2.5 to 1.4.
Guidance, Outlook, and Risks
- Outlook: Management expects fiscal 2001 conductive sales to be comparable to fiscal 2000. Therapeutic patch sales are expected to represent an increased percentage of total net sales due to continued growth in acne products and new Triaminic(R) Vapor brand patches. International sales are expected to be comparable to 2000 levels.
- Capital Resources: The company finalized a $2,000,000 asset-based line of credit in November 1999, with $837,542 outstanding at year-end. The company was in default of covenants (minimum book net worth and maximum loss) at June 30, 2000, but these defaults were waived by the bank in September 2000.
- Risks:
- Customer Concentration: Spacelabs Burdick Inc. accounted for 17% of total sales in 2000. Loss of this customer could have a material adverse effect.
- Liquidity: Funding future operations may require additional equity or debt investments. There is no assurance that capital infusions will be available.
- Competition: The markets for electrodes and OTC patches are highly competitive, with major competitors (e.g., Tyco International) possessing significantly greater resources.
- Unusual Items: The $730,000 charge related to the medical tape exit plan was a significant non-recurring item impacting the bottom line.
Investor Verification Checklist
- Covenant Compliance: Verify the terms of the amended credit agreement and the company's ability to maintain compliance with revised financial covenants.
- Medical Tape Exit: Confirm the timeline and proceeds from the liquidation of medical tape inventory and sale of related assets (expected by Dec 31, 2000).
- Customer Concentration: Assess the stability of the relationship with Spacelabs Burdick Inc. (17% of sales) and the impact of the new supply agreements with Johnson & Johnson and Novartis.
- Cash Burn Rate: Monitor the rapid depletion of cash reserves (down to ~$100k) and the sufficiency of the $2M line of credit to fund operations through fiscal 2001.
- TheraPatch Growth: Validate the sustainability of the 189% growth in therapeutic consumer products and the success of new retail distribution channels.